(Reuters) - With patents expiring on many of today’s top-selling drugs, the global pharmaceuticals industry badly needs a new generation of blockbusters.
It should get a handful of $1 billion-plus products from the class of 2011, according to figures compiled for the Reuters Health Summit.
Topping the list of hopefuls will be treatments for hepatitis C, lupus and heart problems.
The following are some of the biggest new drugs, listed by expected sales in 2015, that may reach the all-important U.S. market this year:
DRUG COMPANY DISEASE 2015 SALES Benlysta Human Genome Sciences/GlaxoSmithKline lupus $3,548 mln telaprevir Vertex/Johnson & Johnson hepatitis C $3,229 mln apixaban Bristol-Myers/Pfizer coagulation $1,543 mln Brilinta AstraZeneca heart disease $1,385 mln dapagliflozin Bristol-Myers/AstraZeneca diabetes $1,267 mln Yervoy Bristol-Myers melanoma $931 mln boceprevir Merck hepatitis C $606 mln abiraterone J&J cancer $456 mln oxycodone Pfizer pain $450 mln Menhibrix GlaxoSmithKline meningitis $277 mln
Source: Thomson Reuters Pharma, consensus forecasts
Reporting by Ben Hirschler